TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11377314

Group type: EXPERIMENTAL
Intervention: 3D sizing model
Number of subjects: 121

Group type: COMPARATOR
Intervention: DRE estimates
Number of subjects: 121

Group type: COMPARATOR
Intervention: Other scales
Number of subjects: 121
Study: 9692075

Group type: EXPERIMENTAL
Intervention: HRT (estradiol valerate (2 mg) plus cyproterone acetate, 1 mg, sequentially: ClimenR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HRT + Vit D (Climen + vitamin D3, 300 IU/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (16 women who refused all treatment)
Number of subjects: 60
Study: 7925172

Group type: EXPERIMENTAL
Intervention: Vigabatrin (gamma‐vinyl GABA; VGB) as add-on therapy
Number of subjects: 73
Study: 3294079

Group type: EXPERIMENTAL
Intervention: Garren-Edwards gastric bubble (bubble-sham)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham treatment (sham-bubble)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Garren-Edwards gastric bubble (bubble-bubble)
Number of subjects: 90
Study: 31622569

Group type: EXPERIMENTAL
Intervention: Kangaroo position (KP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no KP)
Number of subjects: 44
Study: 29452598

Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic treatment
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 14 days of antibiotic treatment
Number of subjects: 115
Study: 28444396

Group type: EXPERIMENTAL
Intervention: CPAP treatment for at least 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: SDB patients (no CPAP treatment)
Number of subjects: 80
Study: 26333879

Group type: EXPERIMENTAL
Intervention: Software-based self-testing system
Number of subjects: 40
Study: 24134648

Group type: EXPERIMENTAL
Intervention: Low testosterone (LT) defined as TT <300 ng/dL
Number of subjects: 1896

Group type: COMPARATOR
Intervention: Normal weight (BMI <25 kg/m(2))
Number of subjects: 1896

Group type: COMPARATOR
Intervention: Overweight (BMI 25 to <30 kg/m(2))
Number of subjects: 1896

Group type: COMPARATOR
Intervention: Obese (baseline BMI ≥30 kg/m(2))
Number of subjects: 1896
Study: 21146458

Group type: EXPERIMENTAL
Intervention: Automation-assisted reading
Number of subjects: 73266

Group type: COMPARATOR
Intervention: Manual reading
Number of subjects: 73266
Study: 17765011

Group type: EXPERIMENTAL
Intervention: Sleep deprivation (55.5 and 58 hours of continuous wakefulness)
Number of subjects: 26
Study: 17380830

Group type: EXPERIMENTAL
Intervention: Computer-assisted functional endoscopic sinus surgery (CASS)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Functional endoscopic sinus surgery (FESS) without computer assistance
Number of subjects: 95
Study: 14967873

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g x d(‐1) Cr + 140 g x d(‐1) glucose for 7 days, followed by 5 g x d(‐1) Cr + 35 g x d(‐1) glucose for 21 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (160 g x d(‐1) glucose [loading] followed by 40 g x d(‐1) [maintenance])
Number of subjects: 19
Study: 11092065

Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.50 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bromocriptine 3.75 mg
Number of subjects: 20
Study: 9112670

Group type: EXPERIMENTAL
Intervention: Iopromid/Ultravist‐300/Schering AG
Number of subjects: 82

Group type: COMPARATOR
Intervention: Uropolinum, Polfa
Number of subjects: 82
Study: 1519828

Group type: EXPERIMENTAL
Intervention: Budesonide 0.8 mg twice daily for 14 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6832199

Group type: EXPERIMENTAL
Intervention: Prajmalium bitartrate (PB) 80 mg/day for 4 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Disopyramide 400 mg/day for 4 days
Number of subjects: 13
Study: 30454846

Group type: EXPERIMENTAL
Intervention: Melatonin 3mg and gabapentin 900mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Matching placebo capsule and gabapentin 900mg
Number of subjects: 80
Study: 30266003

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 27931305

Group type: EXPERIMENTAL
Intervention: 1000 U C1 INH with 24,000 U rHuPH20
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 2000 U C1 INH with 48,000 U rHuPH20
Number of subjects: 47
Study: 24553190

Group type: EXPERIMENTAL
Intervention: Cervarix®
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Gardasil®
Number of subjects: 91
Study: 22265988

Group type: EXPERIMENTAL
Intervention: Glass-fibre posts (GFP) with metal-ceramic (MC) crowns
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Glass-fibre posts (GFP) with all-ceramic (AC) crowns
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Glass-fibre posts (GFP) with ferrule
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (intact ETC)
Number of subjects: 50
Study: 20465990

Group type: EXPERIMENTAL
Intervention: Interceptor nets treated with alphacypermethrin 0.667% (200mg/m2)
Number of subjects: 19
Study: 17353868

Group type: EXPERIMENTAL
Intervention: Supracervical laparoscopic hysterectomy (SLH)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Total laparoscopic hysterectomy (TLH)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Both SLH and TLH
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Participants weighing more than 100 kg
Number of subjects: 141
Study: 16087941

Group type: EXPERIMENTAL
Intervention: Induction paclitaxel (200 mg/m2)/carboplatin (AUC = 6) followed by TRT 63.0 Gy (arm 1, sequential)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction paclitaxel (200 mg/m2)/carboplatin (AUC = 6) followed by weekly paclitaxel (45 mg/m2)/carboplatin (AUC = 2) with concurrent TRT 63.0 Gy (arm 2, induction/concurrent)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (45 mg/m2)/carboplatin (AUC = 2)/TRT (63.0 Gy) followed by two cycles of paclitaxel (200 mg/m2)/carboplatin (AUC = 6; arm 3, concurrent/consolidation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (arms 1 and 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (arms 2 and 3)
Number of subjects: 0
Study: 11583475

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg/day for the first 3 days, 0.25 mg/kg/day for the next 3 days, and 0.125 mg/kg/day for the 7th day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 50
Study: 9826308

Group type: EXPERIMENTAL
Intervention: Bosentan 200 mg IV
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 7926327

Group type: EXPERIMENTAL
Intervention: Selective dorsal rhizotomy (SDR) followed by one month of physical therapy at the center and a community physical therapy program
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 34
Study: 2688070

Group type: EXPERIMENTAL
Intervention: 30 mg omeprazole once daily for 2 weeks
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 30 mg omeprazole once daily for 4 weeks
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo after 2 weeks of healing
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 129
Study: 1106934

Group type: EXPERIMENTAL
Intervention: Carbamazepine (1,200 mg) and Phenytoin (300 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine (1,200 mg) and Phenobarbital (300 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenytoin (300 mg) and Phenobarbital (300 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine (1,200 mg), Phenytoin (300 mg), and Phenobarbital (300 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine (1,200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenytoin (300 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenobarbital (300 mg)
Number of subjects: 0
Study: 295704

Group type: EXPERIMENTAL
Intervention: Single dental health care instruction
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Oral prophylaxis
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both prophylaxis and dental health care instruction
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 31369090

Group type: EXPERIMENTAL
Intervention: Saturated Fatty Acids (SFA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Polyunsaturated Fatty Acids (PUFA)
Number of subjects: 61
Study: 28329340

Group type: EXPERIMENTAL
Intervention: 100 mg enteric-coated aspirin daily for 5 years
Number of subjects: 19114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study: 27611093

Group type: EXPERIMENTAL
Intervention: Nurse-led collaborative care model (Intervention Group)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Routine treatment (Control Group)
Number of subjects: 325
Study: 24368578

Group type: EXPERIMENTAL
Intervention: Regular exercise program (EXE; N = 6)
Number of subjects: 13
Study: 22889296

Group type: EXPERIMENTAL
Intervention: PRP-A
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: PRP-A and PRP-AP
Number of subjects: 408

Group type: COMPARATOR
Intervention: PRP-AP
Number of subjects: 408

Group type: COMPARATOR
Intervention: Control (school-as-usual)
Number of subjects: 408
Study: 19517208

Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 0
Study: 17300299

Group type: EXPERIMENTAL
Intervention: Minimally invasive endoscopic surgery
Number of subjects: 42
Study: 15041391

Group type: COMPARATOR
Intervention: Muromonab (OKT 3) + Neoral + adjunct + standard prednisone
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Simulect + Neoral + adjunct + steroid sparing
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Simulect + Neoral + adjunct + no prednisone
Number of subjects: 245
Study: 11607869

Group type: EXPERIMENTAL
Intervention: Coordination training in spacecurl, kinaesthetics/back protective patient transfer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untrained individuals)
Number of subjects: 0
Study: 9738728

Group type: EXPERIMENTAL
Intervention: Montelukast (5-mg chewable tablet) once daily in the evening for 2 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 8281660

Group type: EXPERIMENTAL
Intervention: iohexol (low-osmolality contrast agent)
Number of subjects: 2166

Group type: COMPARATOR
Intervention: diatrizoate (high-osmolality contrast agent)
Number of subjects: 2166

Group type: EXPERIMENTAL
Intervention: Algorithm for selective use of low-osmolality agents
Number of subjects: 2166
Study: 2973476

Group type: EXPERIMENTAL
Intervention: 2% ketoconazole cream
Number of subjects: 72

Group type: COMPARATOR
Intervention: 1% hydrocortisone cream
Number of subjects: 72
Study: 128306

Group type: EXPERIMENTAL
Intervention: Sch 1000 (10 mug to 80 mug)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sch 1000 (10 to 20 mug)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sch 1000
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 0
Study: 30770523

Group type: EXPERIMENTAL
Intervention: Telehealth-enhanced referral process (video orientation to CMHC and live videoconference CMHC screening visit)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Usual care procedures
Number of subjects: 342
Study: 28728932

Group type: EXPERIMENTAL
Intervention: Complex Restriction (CR)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Simple Restriction (SR)
Number of subjects: 150
Study: 26067687

Group type: EXPERIMENTAL
Intervention: Metformin (escalated from 500 mg to 1000 mg twice daily)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 121
Study: 23941324

Group type: EXPERIMENTAL
Intervention: 12-week endurance training program (exercise group, n = 9)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-exercising control group (n = 6)
Number of subjects: 23
Study: 21806596

Group type: EXPERIMENTAL
Intervention: Lifestyle treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combined intervention and control groups
Number of subjects: 38
Study: 19229946

Group type: EXPERIMENTAL
Intervention: Problem-solving training (PST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 60
Study: 16805713

Group type: EXPERIMENTAL
Intervention: Joint clinical approach to treating allergic rhinitis and asthma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isolated and adjuvant treatment of rhinitis and asthma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical studies regarding joint treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future research directions
Number of subjects: 0
Study: 14671052

Group type: EXPERIMENTAL
Intervention: Haemofiltration (HF) with enoxaparin anticoagulation (single bolus 50 IU/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Haemodiafiltration (HDF) with enoxaparin anticoagulation (single bolus 50 IU/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-flux haemodialysis (HD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Haemofiltration (HF) with enoxaparin anticoagulation (bolus of 1200 IU followed by 400 IU/h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Haemodiafiltration (HDF) with enoxaparin anticoagulation (bolus of 1200 IU followed by 400 IU/h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-flux haemodialysis (HD) with enoxaparin anticoagulation (bolus of 1200 IU followed by 400 IU/h)
Number of subjects: 10
Study: 10921561

Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (200 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8609658

Group type: EXPERIMENTAL
Intervention: Chemotherapy (four courses of cisplatin [20 mg/m2] and fluorouracil [200 mg/m2], given daily for 5 consecutive days during weeks 1, 4, 7, and 10) plus radiotherapy (three courses of 20 Gy each, given in fractions of 2 Gy per day during weeks 2‐3, 5‐6, and 8‐9)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Radiotherapy alone (70 Gy total dose, given in fractions of 2 Gy per day, 5 days per week)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 157

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 157
Study: 1432254

Group type: EXPERIMENTAL
Intervention: NCEP diet with 12 modified eggs per week
Number of subjects: 98

Group type: COMPARATOR
Intervention: NCEP diet with no whole eggs
Number of subjects: 98
Study: 3906674

Group type: EXPERIMENTAL
Intervention: Piretanide (6 mg once daily)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Piretanide plus triamterene (6 mg + 50 mg once daily)
Number of subjects: 47
Study: 29108532

Group type: EXPERIMENTAL
Intervention: Digital versatile disc/leaflet intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 102
Study: 29097626

Group type: EXPERIMENTAL
Intervention: Standard carbohydrate content (75 g, LCD)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Double carbohydrate content (150 g, HCD)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Overall dataset
Number of subjects: 82

Group type: COMPARATOR
Intervention: Insulin resistance (IR)
Number of subjects: 82
Study: 25315409

Group type: EXPERIMENTAL
Intervention: 30mg morphine hydrochloride
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 24597251

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/d for six months
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 52
Study: 21990420

Group type: EXPERIMENTAL
Intervention: Early initiation of antiretroviral therapy (ART)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (80 unrelated index participants)
Number of subjects: 118
Study: 18671167

Group type: EXPERIMENTAL
Intervention: Four types of spoken sentences presented for immediate free recall: four short simple sentences, eight short simple sentences, four compound sentences, and four random word lists.
Number of subjects: 0
Study: 16756999

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study: 14680073

Group type: EXPERIMENTAL
Intervention: Ozone (0.2 parts per million) for 2 hours
Number of subjects: 22

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 22
Study: 10622295

Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg every 4 or 8 weeks)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Infliximab (10 mg/kg every 4 or 8 weeks)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Placebo plus methotrexate
Number of subjects: 428
Study: 7572705

Group type: EXPERIMENTAL
Intervention: Total energy restriction (84 h fasting)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Carbohydrate restriction (84 h fasting with lipid emulsion infusion for 12-15 h each day)
Number of subjects: 5
Study: 1826506

Group type: EXPERIMENTAL
Intervention: Immunization with bacteriophage phi X174
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Immunization with diphtheria toxoid
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Immunization with tetanus toxoid
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Immunization with H. influenzae polyribose phosphate
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Immunization with Pneumovax
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Immunization with type 3 pneumococcal vaccine
Number of subjects: 11
Study: 7006427

Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Static drainage through a main wound
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Static drainage through a stab incision
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Prolonged drainage (static or suction)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Closed drainage
Number of subjects: 184
Study: 31112610

Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study: 28640217

Group type: EXPERIMENTAL
Intervention: Breastmilk iodine concentration (BMIC)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Iodine intake from food
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Total iodine intake (food and supplements)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Iodine-containing supplement intake
Number of subjects: 175
Study: 25651491

Group type: EXPERIMENTAL
Intervention: Combination treatment (lipid emulsion eye drops, omega-3 supplements, eyelid cleansing wipes)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Warm compresses
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study: 24982065

Group type: EXPERIMENTAL
Intervention: Colistin plus fosfomycin
Number of subjects: 94

Group type: COMPARATOR
Intervention: Colistin alone
Number of subjects: 94
Study: 23014711

Group type: EXPERIMENTAL
Intervention: BAY 79-4980 (35 IU/kg)
Number of subjects: 139

Group type: COMPARATOR
Intervention: rFVIII-FS (25 IU/kg)
Number of subjects: 139
Study: 19283747

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17463192

Group type: EXPERIMENTAL
Intervention: In-home behavioral management program (IHBMP) for 4 months
Number of subjects: 55

Group type: COMPARATOR
Intervention: Telephone support condition (TSC) for 4 months
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: In-home behavioral management program (IHBMP)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Telephone support condition (TSC)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 55
Study: 15996353

Group type: EXPERIMENTAL
Intervention: Bone chips
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bone fill material (Bio-Oss)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 33
Study: 12365085

Group type: EXPERIMENTAL
Intervention: SECURUS manometer
Number of subjects: 3992

Group type: COMPARATOR
Intervention: Aneroid or mercury sphygmomanometer
Number of subjects: 3992
Study: 9834008

Group type: EXPERIMENTAL
Intervention: Current use of any oral contraceptive (OC)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Noncurrent use of oral contraceptives (OC)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Different generations of oral contraceptives
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Coagulation factor VIII
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Other plasmatic factors of the protein C system
Number of subjects: 821
Study: 9691922

Group type: EXPERIMENTAL
Intervention: Leu13‐motilin (KW‐5139) infusion at doses of 2, 4, 8, and 16 pmol/kg/min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl) infusion
Number of subjects: 8
Study: 1681680

Group type: EXPERIMENTAL
Intervention: Zuclopenthixol decanoate (ZPT‐D) 100‐600 mg every 4 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Haloperidol decanoate (HAL‐D) 38‐200 mg every 4 weeks
Number of subjects: 64
Study: 7155965

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX) for 14 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 33
Study: 30704182

Group type: EXPERIMENTAL
Intervention: Lidocaine for local anesthesia (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lidocaine + midazolam + fentanyl (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lidocaine + propofol + sufentanil (Group C)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 120
Study: 28385397

Group type: EXPERIMENTAL
Intervention: L-proline supplementation during early pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no L-proline supplementation)
Number of subjects: 0
Study: 25425587

Group type: EXPERIMENTAL
Intervention: Sit-stand desks (SSDs) used for 4 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sit-stand desks (SSDs)
Number of subjects: 28
Study: 23026681

Group type: EXPERIMENTAL
Intervention: MVe Fitness Chair™
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Traditional resistance training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 26